This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

DiaDexus, Inc. Announces Exclusive U.S. Licensing Deal With Thermo Fisher Scientific To Advance Risk Prediction In Heart Failure

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced an exclusive licensing and supply agreement with Thermo Fisher Scientific Inc., the world leader in serving science with $17 billion in revenues, that will provide diaDexus with the ability to develop and commercialize three independent biomarkers (MR-proADM (midregional pro adrenomedullin), MR-proANP (midregional pro atrial natriuretic peptide), and CT-proET1 (C-terminal pro endothelin-1)) to aid in risk prediction and prognosis for heart failure.

"This licensing agreement significantly expands our pipeline of cardiovascular tests and allows us to utilize the market channel infrastructure we have built for our PLAC® tests by providing our cardiovascular specialty laboratory partners and their physician customers the opportunity to address additional hidden risks for cardiovascular disease," said Brian Ward, Ph.D., diaDexus' president and chief executive officer. "Primary care physicians have told us that they need additional tools to better deliver individualized care to their patients emphasizing the need to identify patients at risk for heart failure years before they may begin to suffer from significant disease. To address this need, we plan to develop three individual diagnostic tests, one per biomarker, which will address different stages of heart failure from prediction, diagnosis and survival. We estimate that the addressable U.S. market for these tests is similar to that of our PLAC test."

Under the terms of the agreement, diaDexus will have exclusive rights to develop and commercialize diagnostic clinical laboratory tests based on these biomarkers in the United States. diaDexus plans to conduct the necessary clinical studies needed to allow for regulatory submission and potential U.S. Food and Drug Administration (FDA) clearance for these tests in the future.

“There is a large unmet clinical need for biomarkers that can identify patients along the spectrum of heart failure progression from disease risk in apparently healthy individuals, to symptomatic heart failure,” said Alan Maisel, MD, professor of Medicine at the University of California, San Diego. “Improved tools for the diagnosis and management of heart failure reduce the risk of administering unnecessary and potentially harmful therapies, and allows for individualization of treatment programs in a disease which is very diverse with respect to diagnosis and disease progression.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs